Risperidone in elderly schizophrenic patients - An open-label trial

被引：29

作者：

Berman, I ^{[1
]}

Merson, A ^{[1
]}

RachovPavlov, J ^{[1
]}

Allan, E ^{[1
]}

Davidson, M ^{[1
]}

Losonczy, MF ^{[1
]}

机构：

[1] HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138

来源：

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY | 1996年 / 4卷 / 02期

关键词：

D O I：

10.1097/00019442-199621420-00010

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

The authors assessed the safety and efficacy of risperidone in a group of elderly, patients with chronic schizophrenia and behavioral disturbances (N = 10). There were no clinically significant changes on physical examination. Also, schizophrenic symptoms and cognitive performance improved during risperidone administration. Patients showed a sufficient improvement in both areas to warrant a larger, double-blind study assessing the effects of risperidone on cognitive and psychiatric symptoms in elderly psychotic patients.

引用

页码：173 / 179

页数：7

共 50 条

[31] Open-label trial of nefazodone for depression in CHF patients
Lespérance, F
Frasure-Smith, N
PSYCHOSOMATIC MEDICINE, 2001, 63 (01): : 163 - 164
[32] Open-label trial with olanzapine:: Quality of life and psychosocial functioning in schizophrenic patients with primary positive or negative symptomatology
Dittmann, RW
Mann, K
Müller, MJ
Müller-Siecheneder, F
Röschke, J
Rossbach, W
Russ, H
Wetzel, H
Benkert, O
SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 185 - 185
[33] Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients
Ishigooka, J
Murasaki, M
Miura, S
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2000, 54 (04) : 467 - 478
[34] A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial
D. V. Jeste
Mark Klausner
Martin Brecher
Christopher Clyde
Robert Jones
Psychopharmacology, 1997, 131 : 239 - 247
[35] A clinical evaluation of risperidone in the treatment of schizophrenia: A 10-week, open-label, multicenter trial
Jeste, DV
Klausner, M
Brecher, M
Clyde, C
Jones, R
Abuzzahab, FS
Ahmad, A
Ahmed, S
Ainslie, G
Alidon, G
Jampala, VC
Andriulli, G
Ashleigh, EA
Aukstuolis, J
Bacon, RJ
Badhiwala, SP
Bagri, KS
Baldwin, JD
Bardinelli, AJ
Baron, D
Bartholow, G
Beach, RL
Bera, RB
Berkey, R
Bird, LJ
Boyer, W
Escalona, R
Caccioppoli, G
Taliaferro, J
Carter, RG
Centric, RW
Charalampous, KD
Chastek, JW
Chauhan, N
Cho, SN
Cohen, AJ
Cohn, CK
Corder, SL
Cuervo, MS
Cutler, MO
Damera, BR
Hamilton, RS
Daniels, K
Daskalov, Z
David, A
Davis, H
deLeon, J
Dellario, AV
Dirksen, JS
DosSantos, E
PSYCHOPHARMACOLOGY, 1997, 131 (03) : 239 - 247
[36] An open-label extension study of lurasidone in patients with schizophrenia previously randomized to lurasidone or risperidone
Mattingly, G.
Tocco, M.
Cucchiaro, J.
Xu, J.
Pikalov, A.
Loebel, A.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S559 - S559
[37] Improvement in global functioning in bipolar patients: Results from an open-label, risperidone study
Rupnow, M
Canuso, C
Janicak, P
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S328 - S328
[38] Open-label risperidone treatment of 6 children and adolescents with autism
Vercellino, F
Zanotto, E
Ravera, G
Veneselli, E
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2001, 46 (06): : 559 - 560
[39] An open-label pilot study of risperidone in the treatment of methamphetamine dependence
Meredith, Charles W.
Jaffe, Craig
Yanasak, Elisia
Cherrier, Monique
Saxon, Andrew J.
JOURNAL OF PSYCHOACTIVE DRUGS, 2007, 39 (02) : 167 - 172
[40] Haloperidol prophylaxis does not prevent postoperative delirium in elderly patients: a randomized, open-label prospective trial
Shinji Fukata
Yasuji Kawabata
Ken Fujisiro
Yuichi Katagawa
Kojiro Kuroiwa
Hirotoshi Akiyama
Yasuhito Terabe
Masahiko Ando
Takashi Kawamura
Hideyuki Hattori
Surgery Today, 2014, 44 : 2305 - 2313

← 1 2 3 4 5 →